Candriam S.C.A. Sells 22,528 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Candriam S.C.A. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 173,146 shares of the biopharmaceutical company’s stock after selling 22,528 shares during the quarter. Candriam S.C.A.’s holdings in Regeneron Pharmaceuticals were worth $131,771,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Ethic Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 3.1% during the third quarter. Ethic Inc. now owns 16,570 shares of the biopharmaceutical company’s stock worth $12,564,000 after purchasing an additional 501 shares during the period. Parallel Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 8.9% in the 3rd quarter. Parallel Advisors LLC now owns 1,158 shares of the biopharmaceutical company’s stock valued at $878,000 after acquiring an additional 95 shares in the last quarter. Abacus Wealth Partners LLC lifted its position in shares of Regeneron Pharmaceuticals by 5.4% during the 3rd quarter. Abacus Wealth Partners LLC now owns 722 shares of the biopharmaceutical company’s stock valued at $547,000 after acquiring an additional 37 shares during the period. United Advisor Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 12.2% during the 3rd quarter. United Advisor Group LLC now owns 376 shares of the biopharmaceutical company’s stock worth $285,000 after purchasing an additional 41 shares in the last quarter. Finally, Plancorp LLC grew its holdings in shares of Regeneron Pharmaceuticals by 2.3% during the 3rd quarter. Plancorp LLC now owns 928 shares of the biopharmaceutical company’s stock worth $704,000 after purchasing an additional 21 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on REGN. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the company an “equal weight” rating in a research note on Monday, November 2nd. Robert W. Baird boosted their target price on shares of Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the company a “neutral” rating in a research report on Monday, November 2nd. Wells Fargo & Company upped their price target on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the stock an “equal weight” rating in a report on Monday, November 2nd. Raymond James Financial lifted their price objective on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Finally, Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $898.97.

Insider Activity

In related news, insider Andrew J. Murphy sold 4,147 shares of the firm’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares in the company, valued at $36,960,559.10. This trade represents a 7.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $900.00, for a total transaction of $360,000.00. Following the sale, the director directly owned 603 shares in the company, valued at $542,700. The trade was a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 28,228 shares of company stock valued at $25,985,950. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $904.35 on Friday. The company’s 50 day moving average price is $804.38 and its two-hundred day moving average price is $742.81. The firm has a market capitalization of $93.11 billion, a P/E ratio of 19.97, a P/E/G ratio of 1.20 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. Regeneron Pharmaceuticals’s revenue for the quarter was up 36.3% on a year-over-year basis. During the same quarter last year, the business posted $11.83 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.